Walvax沃森生物

CN
EN

Products List

Walvax has successfully developed 7 licensed vaccines, including recently approved 13-valent Pneumococcal Conjugate Vaccine (PCV13-TT), one of the most difficult vaccines to develop in the world.

 

Walvax proactively promotes PQ application of its products, and is proceeding with PQ application of 5 products. In 3 to 5 years, Walvax's WHO-PQ will yield fruitful results, which brings its internationalization to a higher level.

Quick Links

Pipeline
Group ACYW135 Meningococcal Polysaccharide Vaccine

Prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A, C, Y and W135 for use in individuals aged ≥ 2 years.

Group A and C Meningococcal Polysaccharide Vaccine

Prevention of epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A and C for use in individuals aged ≥ 2 years.

Group A and Group C Meningococcal Conjugate Vaccine

Prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for use in infants and children 3 months through 5 years of age.